Conclusions This real-world health economic evaluation along with a comprehensive systematic review suggest that the use of a GLP-1RA versus insulin has a high likelihood of being cost-effective for T2D patients who require intensified injection therapy from a third-party payer, healthcare sector, and societal perspectives
Non-pharmacological approaches such as heat or cold therapy, physiotherapy, and lifestyle modifications should also be considered as part of a comprehensive pain management strategy
The smell, however, is quite strong, so we ultimately cut it from the list
The Australian and New Zealand College of Anaesthetists (ANZCA), the Gastroenterological Society of Australia, the Australian Diabetes Society, and the National Association of Clinical Obesity Services and Australian and New Zealand Metabolic and the Obesity Surgery Society have developed revised recommendations for patients taking GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists prior to anaesthesia or sedation